ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.

Also called NCT03682692

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 560 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03682692
Other papers using this trial's data
  • Antihypertensive treatment effect of two dual therapies according to sodium sensitivity Hypertension research : official journal of the Japanese Society of Hypertension, 2026-02 DOI, PubMed 41053442
  • Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial BMC medicine, 2024-01-24 DOI, PubMed 38263021, PMC10807184 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03682692. Randomized; single masking; primary purpose treatment. Start 2018-06-01 (actual); primary completion 2021-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
Condition
Hypertension
Intervention (Drug)
ACEI/CCB
Intervention (Drug)
ACEI/DIU
Lead sponsor
Shanghai Jiao Tong University School of Medicine (class: other)

Record details

Record id
cardio:ct-nct03682692
Content hash
7b22d71dad53aabfd502e0bbc210afab1ec2b9afc2dc1051a3f839343567be76